Generation and Characterisation of a Canine EGFP-HMGA2 Prostate Cancer In Vitro Model by Willenbrock, Saskia et al.
Generation and Characterisation of a Canine EGFP-
HMGA2 Prostate Cancer In Vitro Model
SaskiaWillenbrock1, SiegfriedWagner1,2, Nicola Reimann-Berg1, MohammedMoulay1, Marion Hewicker-
Trautwein3, Ingo Nolte1, Hugo Murua Escobar1,4*
1 Small Animal Clinic, University of Veterinary Medicine Hannover, Hannover, Germany, 2 Institute of Biophysics, Leibniz University Hannover, Hannover, Germany,
3Department of Pathology, University of Veterinary Medicine Hannover, Hannover, Germany, 4Division of Medicine, Haematology, Oncology and Palliative Medicine,
University of Rostock, Rostock, Germany
Abstract
The architectural transcription factor HMGA2 is abundantly expressed during embryonic development. In several malignant
neoplasias including prostate cancer, high re-expression of HMGA2 is correlated with malignancy and poor prognosis. The
let-7 miRNA family is described to regulate HMGA2 negatively. The balance of let-7 and HMGA2 is discussed to play a major
role in tumour aetiology. To further analyse the role of HMGA2 in prostate cancer a stable and highly reproducible in vitro
model system is precondition. Herein we established a canine CT1258-EGFP-HMGA2 prostate cancer cell line stably
overexpressing HMGA2 linked to EGFP and in addition the reference cell line CT1258-EGFP expressing solely EGFP to
exclude EGFP-induced effects. Both recombinant cell lines were characterised by fluorescence microscopy, flow cytometry
and immunocytochemistry. The proliferative effect of ectopically overexpressed HMGA2 was determined via BrdU assays.
Comparative karyotyping of the derived and the initial CT1258 cell lines was performed to analyse chromosome
consistency. The impact of the ectopic HMGA2 expression on its regulator let-7a was analysed by quantitative real-time PCR.
Fluorescence microscopy and immunocytochemistry detected successful expression of the EGFP-HMGA2 fusion protein
exclusively accumulating in the nucleus. Gene expression analyses confirmed HMGA2 overexpression in CT1258-EGFP-
HMGA2 in comparison to CT1258-EGFP and native cells. Significantly higher let-7a expression levels were found in CT1258-
EGFP-HMGA2 and CT1258-EGFP. The BrdU assays detected an increased proliferation of CT1258-HMGA2-EGFP cells
compared to CT1258-EGFP and native CT1258. The cytogenetic analyses of CT1258-EGFP and CT1258-EGFP-HMGA2 resulted
in a comparable hyperdiploid karyotype as described for native CT1258 cells. To further investigate the impact of
recombinant overexpressed HMGA2 on CT1258 cells, other selected targets described to underlie HMGA2 regulation were
screened in addition. The new fluorescent CT1258-EGFP-HMGA2 cell line is a stable tool enabling in vitro and in vivo
analyses of the HMGA2-mediated effects on cells and the development and pathogenesis of prostate cancer.
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Introduction
According to recent global cancer statistics, prostate cancer is
the second most frequent diagnosed cancer and sixth leading cause
of death among males in economically developed countries [1].
Besides man, the dog is the only known domesticated mammalian
species developing spontaneous prostate cancer with considerable
interest [2].
Unlike the situation in men, the incidence of canine prostate
carcinomas is low accounting for 0.2 to 0.6% of canine neoplasias
[3]. However, the disease is locally invasive in both species with a
comparable progression, metastatic pattern and histopathology
[2,4].
The mean age at diagnosis in dogs is ten years and thus,
predominantly affecting elder individuals as it is also reported in
men [5–7]. Considering the physiologic age at prostate cancer
diagnosis, the respective life span is similar between the two species
showing increased incidence with age [6].
In humans, prostate cancer is usually a rather slow-progressing
cancer whereas canine prostate cancer is growing rapidly, highly
aggressive and less differentiated presenting a poor prognosis [3,8].
Cancer of the canine prostate gland is unresponsive to androgen
withdrawal therapy resembling mostly human poorly differentiat-
ed, androgen refractory prostate cancer [4,9]. Due to the
similarities concerning the presentation of human and canine
prostate cancer, the dog has lately been focused as useful natural
complementary animal model for evaluating novel prostate cancer
therapies [10].
Early detection of prostate cancer in men is currently being
done using established biochemical molecular markers such as
prostate specific antigen (PSA) and prostate specific membrane
antigen (PSMA) with considerable success.
In comparison to the situation in humans, in dogs prostate
cancer is diagnosed at a very late disease stage due to the absence
of reliable prostate-specific biochemical prognostic marker tools
and the treatment remains palliative since still no standard
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therapeutic approach for treatment of canine prostate cancer is
available [11,12]. Although several studies report immunoreactiv-
ity for human PSA in canine non-neoplastic prostate tissue and
prostate cancer, up to now PSA could not be found in the plasma
of prostate cancer bearing dogs [9,12–16].
Consequently, the identification of reliable molecular biomark-
ers, such as PSA and PSMA in men, allowing an early detection
and reliable prognosis of canine prostatic cancer would be of
significant value for future development and evaluation of
therapeutic strategies as well as the assessment of treatment
response [2].
In this context the High-Mobility-Group Protein A2 (HMGA2)
was recently found to serve potentially as a prognostic marker for
canine prostatic neoplasias [17]. Herein, the analysis of a subset of
different canine prostate tissue samples clearly showed that
expression of HMGA2 increases significantly in correlation to the
malign grade of the tissue samples [17]. Furthermore, HMGA2 was
found to serve as a potential differentiation marker of canine
malignant T- and B-cell lymphoma [18] and to be strongly
upregulated in canine oral squamous cell carcinoma (unpublished
data).
In humans, a re-expression of HMGA2 was also found in various
malignant tumours such as leukaemia [19,20], lymphoma [18],
mammary [21], pancreas [22], non-small cell lung [23], oral
squamous cell [24], and thyroid carcinoma [25] being an indicator
of poor prognosis. In a recent study, the HMGA2 protein
expression was demonstrated to be significantly higher in tumour
tissues compared with adjacent normal tissues [26]. In addition, an
HMGA2 involvement in the induction of epithelial-to-mesenchy-
mal transition (EMT) in the human prostate cancer cell line PC-3
was found [26].
These findings suggest that HMGA2 plays a central role in
different tumour entities including prostate cancer within both
species strongly supporting HMGA2 re-expression as a prognostic
tumour marker.
In general, the highly conserved HMGA2 protein is abundantly
expressed during embryonic development acting as an architec-
tural transcription factor in the nucleus [27,28]. Within this role,
HMGA2 is widely reported to be involved in a variety of cellular
processes such as gene expression, induction of neoplastic
transformation, and promotion of metastasis [29,30].
The expression of HMGA2 is regulated via micro RNAs
(miRNA) of the let-7 family by binding to sequences located in
the 39 untranslated region (UTR) of the transcript [31–35], all of
which are conserved in rodents, dog, and chicken [36–38].
Binding of let-7 miRNAs to complementary sequences regulates
post-transcriptionally the expression of HMGA2 in a negative way
[31,35,39,40]. Recently a deregulated let-7 expression was
associated with lung [41,42], breast [43] and prostate cancer [44].
The canine prostate adenocarcinoma derived cell line CT1258
[45–47] used within the present study was also analysed for
HMGA2 marker expression by us revealing a strong overexpres-
sion (unpublished data). This result allows to hypothesise that an
overexpression of this target gene is likely to play an important role
in canine prostate cancer, promoting the proliferation of tumour
cells.
To verify this hypothesis, the availability of stable tools allowing
evaluating the described HMGA2-let-7 axis in prostate cancer
in vitro and in vivo is precondition. Therefore we established stably
transfected cell lines of CT1258 providing a reliable in vitro system
to analyse the key aspects of our hypothesis.
We analysed the proliferative effects of abundantly expressed
recombinant HMGA2 on CT1258 cells. Therefore, a stable
CT1258 cell line expressing recombinant EGFP-tagged HMGA2
(CT1258-EGFP-HMGA2) was generated using an expression
vector construct containing the coding sequence (CDS) of the
canine HMGA2 gene lacking the 59UTR and 39UTR and
therefore not underlying the direct negative regulation mecha-
nisms by let-7 [31].
To assess the functionality of the recombinant HMGA2
expression vector and to monitor the biological activity of the
recombinant expressed HMGA2, a GFP-tag was added to the
HMGA2 CDS generating a HMGA2-GFP fusion protein. To
exclude that the GFP protein has an effect on cell proliferation, a
further stable CT1258 cell line (CT1258-EGFP) expressing solely
GFP was generated. The HMGA2 and let-7a expression was
determined via quantitative real-time PCR in CT1258-EGFP-
HMGA2 and CT1258-EGFP in comparison to native CT1258
cells.
Additionally, the expression of selected direct and indirect
HMGA2-targets such as HMGA1 [48], SNAI1 [49], SNAI2 and
CDH1 [49] was analysed.
To characterise the proliferation of the described three cell lines,
BrdU incorporation assays were performed. Comparative karyo-
type analyses of the newly generated and the initial CT1258 cell
lines were additionally carried out to identify cytogenetic changes
possibly occurring during plasmid integration into the genome of
CT1258 during the establishment of the stable recombinant cell
lines.
In summary the new fluorescent canine CT1258-EGFP-
HMGA2 cell line provides a valuable tool for further investigations
on HMGA2-mediated proliferative effects and HMGA2 regula-
tion mechanisms elucidating the development and pathogenesis of
canine prostate cancer. As the dog represents a unique natural
model for human prostate cancer, the insights concerning the
involvement of HMGA2 in canine prostate cancer will provide
benefit for both, humans and dogs, concerning the development of
therapeutic strategies and the assessment of the treatment success.
Methods
CT1258 Cell Line
The cell culture conditions, as well as the characteristics of the
canine prostate carcinoma cell line CT1258 have been described
previously by us [45,46].
pEGFP-C1-HMGA2 Expression Plasmid
The protein coding sequence of the canine HMGA2 was
amplified by PCR using primer pair EcoRI_sA2_lo (59-
CGGAATTCCTAGTCCTCTTCGGCAGACT-39), BamHI_-
sA2_Up (59-CGGGATCCCACCATGAGCGCACGCGGT-39).
The obtained PCR products were separated on a 1.5% agarose
gel, recovered with QIAquick Gel Extraction Kit (QIAGEN,
Hilden, Germany), ligated in the pEGFP-C1 vector plasmid (BD
Bioscience Clontech, Palo Alto, CA, USA) and sequenced for
verification. Transfection with the pEGFP-C1-HMGA2 construct
leads to the expression of a recombinant EGFP-HMGA2 fusion
protein which is expected to be localised in the nucleus.
Generation of Fluorescent CT1258 Cell Lines
Transfection of CT1258 cells. 300,000 native CT1258 cells
were seeded in 6-well plates 24 hours prior transfection and
cultivated at standard conditions using medium 199 (Life
Technologies GmbH, Darmstadt, Germany) supplemented with
10% FCS (PAA Laboratories GmbH, Coelbe, Germany), and 2 %
penicillin/streptomycin (Biochrom AG, Berlin, Germany).
The transfection was performed according to the manufactur-
er’s instructions using 7.5 ml Mirus TransIT-2020 reagent
Canine EGFP-HMGA2 Prostate Cancer In Vitro Model
PLOS ONE | www.plosone.org 2 June 2014 | Volume 9 | Issue 6 | e98788
(Mirusbio LLC, Madison, WI, USA) in 250 ml serum-reduced
Opti-MEM I medium (Life Technologies, Darmstadt, Germany)
containing 2.5 mg of pEGFP-C1 (BD Bioscience Clontech, Palo
Alto, CA, USA) or recombinant pEGFPC1-HMGA2 plasmid.
After treatment, the cells were incubated for 24 hours in the
culture media. The uptake and expression of DNA was verified by
fluorescence microscopy using a Leica DMI 6000B fluorescence
microscope (Leica Microsystems GmbH, Wetzlar Germany).
G418 selective antibiotic kill curve assay. Prior genera-
tion of the fluorescent CT1258 cell lines, the titration of the proper
amount of the selective antibiotic G418 (syn. Geneticin; Life
Technologies, Darmstadt, Germany) required for selection of
CT1258 cells was carried out with a kill curve assay. Different
G418 concentrations were applied (0, 100, 200, 400, 600, 800,
1000 mg/ml) on 100,000 native CT1258 cells seeded in the wells
of a 12-well plate. For selection of positive cells after transfection
the concentration was used in which no cell survived the upper
conditions after seven days.
Selection of positively transfected CT1258
cells. Fluorescent variants of the cell line CT1258 were
established to constitutively express the enhanced green fluores-
cent protein (EGFP) encoded by the empty pEGFP-C1 plasmid
and an EGFP-HMGA2 fusion protein by expression of the
recombinant pEGFP-C1-HMGA2 plasmid. To establish the stable
CT1258 cell lines, the transfected cells were selected with the
antibiotic G418 (Life Technologies, Darmstadt, Germany).
Initially a concentration of 400 mg/ml G418 in the medium was
used when selecting for stable cells. One day after transfection, the
cultivation medium 199 was replaced with medium 199 containing
G418. Subsequently the selection medium was changed each 24 to
48 hours for the first two weeks which leads to the selection of cells
that have stably incorporated the GFP plasmid with the encoded
antibiotic resistance gene neomycin for selection in mammalian
cells into their genomic DNA. Cells not expressing the construct
will be killed by G418. The concentration of G418 was lowered to
300 mg/ml after three months of consistent selection for mainte-
nance of the generated fluorescent cell lines.
Fluorescence Microscopy and Flow Cytometry (FCM)
GFP expression of the fluorescent cell lines CT1258-EGFP and
CT258-EGFP-HMGA2 was analysed after G418-selection by
fluorescence microscopy and quantified in a FACSCalibur flow
cytometer (Becton, Dickinson and Company, Heidelberg, Ger-
many) with the FL-1 channel to determine the percentage of GFP-
positive cells. Cells were trypsinised for 3–5 min, resuspended in
BD FACSFlow Sheath Fluid (Becton, Dickinson and Company,
Franklin Lakes, NJ, USA) containing 1 mM TO-PRO-3 (Life
Technologies GmbH, Darmstadt, Germany), and at a total
number of 16104 events was measured for each sample by flow
cytometry. TO-PRO-3 is a far-red cell impermeant nucleic acid
stain measured in the FL-4 channel allowing ultrasensitive
detection of double-stranded DNA of dead cells. The analysis of
the flow cytometry data was done using with Cell Quest software
(Becton, Dickinson and Company, Franklin Lakes, NJ, USA).
Immunocytochemistry
Embedding of the cell lines. Cell suspensions of cultured
cell lines were fixed in 4% formalin. Cell pellets obtained by
centrifugation were embedded in paraffin and cut in 3–4 mm slices
for immunocytochemical staining.
Immunocytochemical staining. For antigen retrieval, mi-
crowave heating of paraffin sections in 0.01 M citric acid buffer
(pH 6.0 for 20 min) (Quartett, Berlin, Germany) was performed.
The inhibition of endogenous peroxidase activity was achieved by
immersion in 0.5% H2O2 (v/v) in methanol (20 min). After
draining the blocking serum the sections were incubated with a
polyclonal goat anti-human HMGA2 antibody (R & D Systems,
Minneapolis, MN, USA) diluted 1:400 in phosphate-buffered
saline (PBS, pH 7.2, 0.15 M) approximately 16–18 h at 4uC. After
washing in PBS, the sections were incubated with a biotin-
conjugated antibody to goat IgG (Vector Laboratories, Burlin-
game, CA, USA). The avidin-biotin-peroxidase reagent (Vector
Laboratories) was applied according to the manufacturers
instructions. The chromogen used was 393-diaminobenzidine-
tetrahydrochloride (Sigma Aldrich, Mu¨nchen, Germany) 0.05%
(w/v) with 0.03% H2O2 (v/v) as substrate in 0.1 M Tris-buffered
saline (Tris-hydroxymethyl-aminomethane; Merck, Darmstadt,
Germany). The sections were counterstained with Mayers
haematoxylin and mounted. Negative controls were performed
by replacing the primary antibodies by normal goat serum. For
establishing the immunocytochemical staining reactions, paraffin
sections from a canine oral squamous cell carcinoma were used.
RNA Isolation and cDNA Synthesis
Total RNA of the EGFP and EGFP-HMGA2 expressing as well
as native CT1258 cells were isolated using the NucleoSpin
miRNA (Macherey-Nagel, Du¨ren, Germany) kit according to the
manufacturer’s instructions including an on column DNase digest
to remove potential genomic DNA contaminations.
The respective cDNA syntheses with mRNAs as template were
performed using 250 ng total RNA of each sample and the
QuantiTect Reverse Transcription Kit following the manufactur-
er’s protocol (Qiagen, Hilden, Germany).
For the reverse transcription of the miRNAs 30 ng total RNA of
each sample, the TaqMan MicroRNA Reverse Transcription Kit
and the reverse transcription primer provided with the TaqMan
MicroRNA Assays were used. All steps were carried out following
the manufacturer’s protocol (Applied Biosystems, Darmstadt,
Germany).
HMGA1, HMGA2, SNAI1, SNAI2 and CDH1 Real-time PCR
For relative quantification of the HMGA2, HMGA1, SNAI1,
SNAI2 and CDH1 transcript levels in relation to the endogenous
gene controls GUSB and HPRT1 PCR amplifications were carried
out using the Eppendorf Mastercycler ep realplex real-time PCR
System (Eppendorf AG, Hamburg, Germany).
2 ml of each cDNA corresponding to 25 ng of total RNA were
amplified in a total volume of 20 ml using the TaqMan Universal
PCR Master Mix (Applied Biosystems, Darmstadt, Germany) with
600 nM of each primer and 200 nM fluorogenic probe for canine
HMGA1, HMGA2 gene expression analysis (previously published
by us in Joetzke et al. [18]. Commercially available TaqMan gene
expression assays were used for the analysis of the canine targets
SNAI1 (Cf02705362_s1), SNAI2 (Cf02701218_u1) and CDH1
(Cf02697525_m1) as well as for the endogenous controls, canine
GUSB (Cf02622808_m1) and canine HPRT1 (Cf02626258_m1)
(Applied Biosystems, Darmstadt, Germany).
PCR conditions were as follows: 2 min at 50uC and 10 min at
95uC, followed by 40 cycles with 15 s at 95uC and 1 min at 60uC.
All samples were measured in triplicate and for each run non-
template controls and non-reverse transcriptase control reactions
were included. A precedent efficiency analysis of all PCR assays
used in this study was performed by applying the same template in
different dilution steps covering a magnitude of five (cDNA
corresponding to 100–0.001 ng RNA). The PCR reactions of all
analysed target genes showed comparable efficiencies ensuring an
appropriate relative real-time PCR analysis. For the analysis based
on DDCT method native CT1258 cells were defined as calibrator.
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Let-7a, RNU6B Real-time PCR
Relative quantification of the canine let-7a and RNU6B miRNA
transcript levels were carried out using the Eppendorf Mastercy-
cler ep realplex real-time PCR System (Eppendorf AG, Hamburg,
Germany). 1.33 ml of each cDNA were amplified in a total volume
of 20 ml using TaqMan Universal PCR Master Mix (Applied
Biosystems, Darmstadt, Germany), No AmpErase UNG and
TaqMan MicroRNA assays for let-7a (Assay ID: 000377) and
RNU6B (Assay ID: 001093) (Applied Biosystems, Darmstadt,
Germany).
PCR conditions were as follows: 10 min at 95uC, followed by 40
cycles with 15 s at 95uC and 1 min at 60uC.
All samples were measured in quadruplicate and for each run
non-template controls and non-reverse transcriptase control
reactions were included.
A precedent efficiency analysis of the miRNA PCR assays which
were used in this study was performed by applying the same
template in different dilution steps, showing comparable efficien-
cies. For the analysis based on DDCT method the control group
was defined as calibrator performing relative real-time PCR with
let-7a as target gene.
Real-time PCR Statistical Analysis
Statistical analysis of the relative real-time PCR results was
performed applying the hypothesis test with the software tool
REST 2009, version 2.0.13 (Qiagen, Hilden, Germany) [50].
REST determines whether there is a significant difference between
samples and controls taking into account reaction efficiencies and
using randomisation techniques. A p-value of #0.05 was
considered to be statistically significant.
Cell Proliferation Assay
The proliferation of native CT1258 cells in comparison to the
established fluorescent CT1258-EGFP and CT1258-EGFP-
HMGA2 cell lines was evaluated using a colorimetric BrdU cell
proliferation ELISA (Roche Applied Science, Mannheim, Ger-
many). This assay measures the incorporation of the thymidine
analogue 5-bromo-2-deoxyuridine (BrdU) into newly synthesised
DNA of replicating cells by ELISA using an anti-BrdU monoclo-
nal antibody.
A total number of 15.000 cells/well from each CT1258 cell line
was seeded in eight different wells and cultivated at the previously
described conditions. BrdU was added after 24 h and incubated
for two hours. The proliferation assay was carried out according to
manufacturer’s protocol (Cell proliferation ELISA, colorimetric,
Roche Applied Science, Mannheim, Germany). The reaction
products were quantified by measuring the absorbance at 370 nm
(reference wavelength 492 nm) with a maximum of 27 single reads
over a time period of 30 min using a scanning multi-well
spectrophotometer equipped with the analysis software Gen 5
(Synergy HT multi-mode microplate reader, BioTek Instruments
Inc., Bad Friedrichshall Germany). The absorbance results directly
correlate to the amount of DNA synthesis and hereby to the
number of proliferating cells.
Results are stated as mean absorbance values expressed as Max
V [delta 370–492] and presented as mean 6 standard deviation.
All statistical analyses were performed using OriginPro 8 software
(OriginLab Corporation, Northampton, USA). The Shapiro-Wilk
test was applied to test if the data are normally distributed. Based
on the outcome of the Shapiro-Wilk test, a paired sample t-test was
performed to assess the significance of proliferative differences
between CT1258-EGFP, CT1258-EGFP-HMGA2 and native
CT1258 cells. Differences were considered statistically significant
for * p#0.05, ** p#0.001 to 0.01 and *** p,0.001.
Chromosome Preparation
For chromosome preparation of CT1258-EGFP and CT1258-
EGFP-HMGA2 cells colcemid (Biochrom AG, Berlin, Germany)
was added at a final concentration of 0.1 mg/ml for 90 min before
harvesting. Subsequently, the cells were incubated for 20 min in
hypotonic medium (1: 6; medium 199: H2O; (medium 199: Life
Technologies GmbH, Darmstadt, Germany)) and finally fixed
with methanol/glacial acetic acid (3:1) following routine methods
[51]. The suspension was dropped on ice-cold slides and dried for
5 days at 37uC followed by GTG-banding which was performed as
previously described by [52]. Results were processed and recorded
with BandView, 6.0, MultiSpecies, Applied Spectral Imaging,
Israel. Karyotype description followed the nomenclature proposed
by Reimann et al. [53].
Results
Fluorescence Microscopy and FCM
Fluorescence microscopy. CT258 cells transfected with the
non-recombinant pEGFP-C1 expression vector showed green
fluorescence all over the cytoplasm due to EGFP expression
(Fig. 1B) whereas unmodified native CT1258 cells showed no
EGFP fluorescence (Fig. 1A).
Transfection of CT1258 with pEGFPC1-HMGA2 resulted in
the expression of a recombinant canine EGFP-HMGA2 fusion
protein which could solely be detected in the nucleus of the
transfected cells (Fig. 1C).
FCM. For determination of EGFP positive cells by FCM,
both fluorescent cell lines were compared to native non-transfected
CT1258 cells (Fig. 1D). Dead, TO-PRO-3 positive cells were
eliminated by gating prior to the EGFP positivity analysis. The
cells were measured for CT1258 in the 319th passage, for
CT1258-EGFP in the 27th passage, and for CT1258-EGFP-
HMGA2 in the 113th passage.
The vitality of the cell lines ranged from 85% to 93% (data not
shown). A mean percentage of 84.1% EGFP positive cells from the
total cell population of the G418 selected CT1258-EGFP cell line
(Fig. 1E) and 97.0% EGFP positive cells for the CT1258-EGFP-
HMGA2 cell line (Fig. 1F) was determined.
Immunocytochemistry
Approximately 50% of the CT1258-EGFP cell line had nuclear
labelling for HMGA2 (Fig. 2B). In approximately 70–80% of
CT1258-EGFP-HMGA2 cells strong labelling for HMGA2 was
detected, which was exclusively present in the nucleus (Fig. 2C).
Relative HMGA2 Real-time PCR Expression Analysis
All real-time PCR results were analysed based on DDCT
method. The expression ratio of HMGA2 mRNA in CT1258-
EGFP cells was found to be 0.88/0.92 relative to HPRT1/GUSB
expression when compared to the level seen in native CT1258 cells
(Fig. 3). In contrast, the HMGA2 expression in CT1258-EGFP-
HMGA2 cells was 7.0/8.0 fold increased (relative to HPRT1/
GUSB) when compared to the respective expression in native
CT1258 cells (Fig. 3).
Relative Let-7a Real-time PCR Expression Analysis
The let-7a expression level in CT1258-EGFP and CT1258-
EGFP-HMGA2 cells was 2.0 and 3.1 fold higher (relative to
RNU6B) when compared to the detected expression in native
CT1258 cells (Fig. 4).
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Relative HMGA1 Real-time PCR Expression Analysis
The HMGA1 level was 1.5 and 1.7 fold increased (relative to
HPRT1 and GUSB) in CT1258-EGFP-HMGA2. In CT1258-
EGFP cells a comparable increased expression could not be
detected (1.0/1.0 relative to HPRT1 and GUSB) when compared
to the native cells (Fig. 5).
Relative SNAI1, SNAI2 and CDH1 Real-time PCR Expression
Analysis
Relative SNAI1 expression to the housekeeping genes HPRT1/
GUSB was found to be 0.8/0.8 respectively in CT1258-EGFP and
1/1.2 in the CT1258-EGFP-HMGA2 when compared to native
cells CT1258 (figure S1).
Relative SNAI2 expression (relative to HPRT1/GUSB) was
found 1.5/1.6 in CT1258-EGFP cells and 1.4/1.6 in CT1258-
EGFP-HMGA2 cells when compared to CT1258 (figure S2).
CDH1 was barely expressed in all cell lines with Ct values higher
than 36, thus an analysis by the DDCT method was not possible.
Real-time PCR Statistical Analysis
The hypothesis test of the relative real-time PCR results was
performed using REST software tool 2009, version 2.0.13
(Qiagen, Hilden, Germany) [50]. The statistical analyses were
carried out separately for the CT1258-EGFP and CT1258-EGFP-
HMGA2 cells in comparison to native CT1258. A p-value of#
0.05 was considered as statistically significant.
The statistical analysis showed no significant differences of the
relative HMGA2 expression in the CT1258-EGFP cells in
comparison to native CT1258 cells (p = 0.075) (Fig. 3). The
CT1258-EGFP-HMGA2 cell line showed a significant HMGA2
over-expression in comparison to native CT1258 cells (p = 0.009)
and CT1258-EGFP cells (p = 0.000) (Fig. 3).
The relative let-7a expression differed significantly in CT1258-
EGFP (p = 0.003) and CT1258-EGFP-HMGA2 (p= 0.012) com-
pared to the native CT1258 cells (Fig. 4). The additional statistical
analysis of the let-7a expression between the CT1258-EGFP and
CT1258-EGFP-HMGA2 cells showed also statistical significance
(p = 0.021).
The HMGA1 showed no statistical difference in CT1258-EGFP
(p = 0.087) but a significantly higher expression level in CT1258-
EGFP-HMGA2 in comparison to the native cell line CT1258
(p = 0.000) and the CT1258-EGFP cells (p = 0.000) (Fig. 5).
SNAI1 expression was statistically significantly different in
CT1258-EGFP in comparison to the SNAI1 levels in the native
Figure 1. Fluorescence microscopy and flow cytometry analyses. A: Transmitted light image of the characteristic growth pattern of native
CT1258 cells. B: Merged image of EGFP expressing CT1258-EGFP cells; EGFP is localised in the cytoplasm. C: Merged image of CT1258-EGFP-HMGA2
cells expressing the nuclear localised EGFP-HMGA2 fusion protein. D–F: Flow cytometric analyses of EGFP expression in the three CT1258 cell lines
depicted in dot-plots showing side scatter (SSC) vs. EGFP fluorescence. No GFP fluorescence is detectable in native CT1258 cells (D), 84.1% of EGFP-
positive cells are present in the CT1258-EGFP cell line and (F) 97.0% EGFP-positive cells in CT1258-EGFP-HMGA2. Per sample 16104 events were
analysed.
doi:10.1371/journal.pone.0098788.g001
Figure 2. Immunocytochemical staining. A: Native CT1258 cells, B: CT1258-EGFP cells, C: CT1258-EGFP-HMGA2 cells. Approximately 50% of the
native CT1258 cell line and of CT1258-EGFP cells showed a HMGA2-positive nuclear labelling. In approximately 70–80% of CT1258-EGFP-HMGA2 cells,
a strong and exclusively nuclear labelling for HMGA2 was detectable.
doi:10.1371/journal.pone.0098788.g002
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Figure 3. HMGA2 real-time PCR analyses. Relative HMGA2/HPRT1 and HMGA2/GUSB expression in native CT1258, CT1258-EGFP and CT1258-
HMGA2-EGFP cells. Error bars are standard deviations. *p#0.05 indicates a statistical significant expression deregulation of HMGA2 in CT1258-
HMGA2-EGFP cells when compared to native CT1258.
doi:10.1371/journal.pone.0098788.g003
Figure 4. Let-7a real-time PCR analyses. Relative let-7a/RNU6B expression in native CT1258, CT1258-EGFP and CT1258-HMGA2-EGFP cells. Error
bars are standard deviations. No statistical significant expression deregulation of let-7a in CT1258-EGFP and CT1258-HMGA2-EGFP was detected when
compared to native CT1258 cells. Statistical significant p value was defined as #0.05.
doi:10.1371/journal.pone.0098788.g004
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cell line (p = 0.016). In CT1258-EGFP-HMGA2 the SNAI1
expression was comparable to native CT1258 cells (p = 0.462)
(figure S1).
SNAI2 expression of CT1258-EGFP (p= 0.100) and CT1258-
EGFP-HMGA2 (p= 0.066) were both not significantly different in
comparison to the native cell line (figure S2). For CDH1 expression
no statistical analyses was performed due to barely detectible or
absent gene expression.
Cell Proliferation Assay
The proliferation of the two established fluorescent CT1258 cell
lines and native CT1258 cells was measured using a BrdU
proliferation test to analyse the effect of EGFP-HMGA2 expressed
in CT1258-EGFP-HMGA2 cells.
The proliferation of each cell line was compared with the two
other cell lines (Fig. 6). A significantly increased cell proliferation
activity with a p-value of ,0.05 was ascertained for CT1258-
EGFP-HMGA2 cells in comparison to native CT1258 cells.
Comparing CT1258-EGFP-HMGA2 cells vs. CT1258-EGFP cells
resulted also in significantly increased cell proliferation for
CT1258 expressing EGFP-HMGA2, but with a p-value of ,
0.01. The analysis of native CT1258 vs. CT1258-EGFP cells
resulted in no significant proliferative differences (p.0.05)
between both cell lines.
Cytogenetic Analyses
The analysis of native CT1258 cells revealed the presence of a
hyperdiploid karyotype (Fig. 7A). Centromeric fusions between the
canine chromosomes 1 (CFA1) and 5 (CFA 5), in the following
named as der(1;5), were present (Fig. 8). Additionally, one large bi-
armed marker (mar) consisting of material from chromosomes 1
and 2 was found (Fig. 8). The gained results are comparable to our
previous cytogenetic analysis of primary CT1258 cells carried out
by Winkler et al. in 2005 [45] concerning the present der(1;5) and
the bi-armed marker chromosome (mar). In contrast, native
CT1258 cells showed no longer the centric fusions of chromo-
somes 4 (CFA4) and 5 (CFA5) (named der(4;5)) as described in
50% of the initially analysed metaphases of primary CT1258 cells
[45].
The chromosome analyses of CT1258-EGFP and CT1258-
EGFP-HMGA2 revealed a comparable hyperdiploid karyotype as
described for native CT1258 cells (Fig. 7B, 7C). The same large bi-
armed marker chromosome (mar) and the two der(1;5) chromo-
somes as described for native CT1258 cells were also present
(Fig. 7B, 7C and Fig. 8).
Figure 5. HMGA1 real-time PCR analyses. Relative HMGA1/HPRT1 and HMGA1/GUSB expression in native CT1258, CT1258-EGFP and CT1258-
HMGA2-EGFP cells. Error bars are standard deviations. *p#0.05 indicates a statistical significant increased expression of HMGA1 in CT1258-HMGA2-
EGFP cells when compared to native CT1258 and CT1258-EGFP.
doi:10.1371/journal.pone.0098788.g005
Figure 6. BrdU cell proliferation assay. Measured proliferation of
native CT1258, CT1258-EGFP and CT1258-HMGA2-EGFP cells. A
statistical significant increased proliferation was detected for CT1258
cells expressing the EGFP-HMGA2 fusion protein in comparison to
native CT1258 and EGFP expressing CT1258 cells. Each bar represents a
mean 6 SD, *p#0.05, ***p#0.001.
doi:10.1371/journal.pone.0098788.g006
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Discussion
Re-expression of HMGA2 is reported to be associated with the
formation of malignant and benign tumours [17–25,54–57], but
the exact mechanism of HMGA2 acting in tumour formation and
progression is still unclear. In general, miRNA let-7 family
members are regulating HMGA2 time-dependently in a negative
way by binding to multiple target sites in the 39UTR of HMGA2
mRNA [31–34,39]. In different tumours, the HMGA2 39UTR was
described to be affected by deletions or rearrangements [58]
leading to a loss of let-7 complementary target sequences [39,59].
A truncated HMGA2 mRNA without let-7 binding sites escapes the
let-7 regulation resulting in increased expression of HMGA2
protein [31,32,39]. Generally, a delicate balance of let-7 and
HMGA2 is discussed to be necessary for cells to switch between
undifferentiated and differentiated state and also plays a central
role in cancer development and progression [33,60–63]. How
HMGA2 exerts these changes is not completely understood.
Within this study, we analysed the described let-7-HMGA2
regulation mechanism in canine prostate cancer using the
naturally HMGA2-overexpressing canine adenocarcinoma de-
rived cell line CT1258 as an in vitro model.
The CT1258 cell line was as previously described to be derived
from an aggressive canine prostate carcinoma [45]. In previous
studies we characterised the in vivo behaviour and tumour
formation capacity of CT1258 in NOD/SCID [47,48]. Herein,
it could be shown that a very low number of 16103 subcutane-
ously injected CT1258 cells [47] and an intraperitoneal inocula-
tion of 16105 cells was sufficient to induce stable tumour growth
[46]. The induced tumours showed highly aggressive growth
mimicking the character of the original neoplasia [46,47].
Comparative analyses of the primary neoplasia, the initial
established CT1258 cell line and the CT1258 generated tumours
showed that the cell line and the induced tumours kept their
characteristics including cytogenetics, marker expression and in
case of the induced tumours the histopathological presentation
[45–47].
Thus, the native CT1258 cell line provides a well-characterised
basis to identify and characterise molecular mechanisms playing a
key role in prostate cancer.
With the recombinant CT1258-EGFP-HMGA2 cell line,
expressing an EGFP-HMGA2 transcript lacking the 39UTR, we
investigated if the proliferative effect of HMGA2 can even be
further enhanced although the endogenous HMGA2 mRNA level
in native CT1258 cells is already highly elevated compared to non-
neoplastic prostate tissue (unpublished data). Moreover, we
analysed the potential impact of the ectopic HMGA2 expression
on the miRNA let-7a as one of its regulators within the CT1258-
EGFP-HMGA2 cell line in comparison to native CT1258 cells
and the control cell line CT1258-EGFP.
In addition the gene expression of the direct HMGA2 target
genes HMGA1, SNAI1, SNAI2 and the downstream target CDH1
were examined [48,49].
Verification using fluorescence microscopy detected high
numbers of EGFP-positive cells expressing either the cytoplasmatic
EGFP protein localised throughout the cell or the EGFP-HMGA2
fusion protein. The EGFP-HMGA2 protein was shown to be
accumulating exclusively into the nucleus as known for the native
protein.
The nuclear accumulation of the recombinant EGFP-HMGA2
fusion protein represents HMGA2-typical characteristics such as a
functional nuclear localisation signal and chromatin-binding
properties enabling proper EGFP-HMGA2 protein function.
Further, an irregular distribution of EGFP-HMGA2 amongst
the chromatin could be observed matching previous reports
characterising native HMGA2 by other groups [49,60,64,65].
This irregular nuclear distribution of HMGA2 could also be
shown by our immunocytochemistry analyses. The results of the
HMGA2 immunocytochemistry revealed a distinct nuclear
labelling in approx. 50% of native and CT1258-EGFP cells, while
70–80% of the CT1258-EGFP-HMGA2 cells showed a strong
nuclear labelling. Due to the strong nuclear signal in the CT1258-
HMGA2-EGFP cells showing the same irregular labelling as seen
by fluorescence microscopy, the presence and the functionality of
the ectopically expressed HMGA2-GFP fusion protein could be
detected via both methodologies.
The flow cytometry analyses confirmed the observed high
numbers of fluorescent cells resulting in 84.1% CT1258-EGFP
Figure 7. Cytogenetic analyses. Metaphase spreads derived from CT1258 (A), CT1258-EGFP (B) and CT1258-EGFP-HMGA2 (C) cells after GTG-
banding. The arrows indicate the centromeric fusions between the canine chromosomes 1 and 5 (der(1;5)) and a large bi-armed marker (mar)
consisting of material from chromosomes 1 and 2 being characteristic for the CT1258 cell line.
doi:10.1371/journal.pone.0098788.g007
Figure 8. Details of CT1258 chromosomal aberrations. Detailed
presentation of chromosomal aberrations found in metaphases of
CT1258, CT1258-EGFP and CT1258-EGFP-HMGA2. Two derivative
chromosomes (der(1;5)) and the large bi-armed marker chromosome
(mar) were found in each cell line.
doi:10.1371/journal.pone.0098788.g008
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and 97.1% CT1258-EGFP-HMGA2 positive cells expressing
EGFP. Thus, the antibiotic selection with G418 showed as very
effective to generate nearly pure recombinant derivatives of the
CT1258 cell line which can be used as a tool for subsequent in vivo
experiments.
Real-time PCR analyses of HMGA2 expression revealed
comparable HMGA2 levels in native CT1258 and CT1258-EGFP
cells while a statistically significant HMGA2 overexpression could
be detected in the CT1258-EGFP-HMGA2 cell line. This leads to
the assumption that by transfection of CT1258 cells with the
pEGFP-C1-HMGA2 expression vector construct and selection
with G418 an ectopic EGFP-HMGA2 expression could be
successfully implemented.
Furthermore, let-7a real-time PCR expression analyses were
performed to investigate potential connections on the HMGA2-let-
7-axis in canine prostate cancer. The results showed significantly
increased let-7a expression levels in CT1258-EGFP and CT1258-
EGFP-HMGA2 in comparison to the native cell line, whereupon
the highest let-7a level was detected in CT1258-EGFP-HMGA2.
The CT1258-EGFP cell line was intended to serve as a control cell
line to exclude EGFP-induced effects. Thus, a comparable let-7a
expression was expected in native CT1258 cells and the CT1258-
EGFP cell line. Interestingly, significantly higher let-7a levels were
found in CT1258-EGFP. This might be explained by off-target
effects induced by the treatment with G418 or the unidentified
integration loci of the expression vector into the genome
potentially affecting let-7a regulatory sites. An effect of EGFP
overexpression on the let-7a expression is unlikely as EGFP was
used as a reporter protein within previously published let-7 studies
showing no EGFP-induced side-effects on let-7 expression [66,67].
As described previously, the recombinant inserted canine
HMGA2 CDS in the CT1258-HMGA2-EGFP cell line is lacking
the 39UTR which was expected to result in an escape of the
recombinant transcript from the let-7a miRNA suppression [31].
Owning to the fact that several protein products encoded by the
let-7a-regulated mRNAs as e.g. Lin-28, Dicer, Myc and Argonaute
[68–71] were reported to constitute a feedback loop with its
regulator, we hypothesized if a HMGA2 protein overexpression
might influence the let-7a level as well. However, a significantly
higher expression of let-7a was detected not only in CT1258-
EGFP-HMGA2 but as well in the CT1258-EGFP control cell line.
Further statistical analysis revealed that the expression of let-7a in
CT1258-EGFP-HMGA2 was not only significantly higher in
comparison to native cells but also in comparison to the CT1258-
EGFP control cell line. It seems that the cells responded to the
elevated levels of the recombinant HMGA2 with increased let-7a
expression. However, the elevated let-7a levels can not solely be
attributed to a direct feedback loop as the one previously described
for the above mentioned let-7 targets [68,70,71]. An alternative,
indirect response of the cells which are ‘‘sensing’’ the HMGA2
overproduction or unspecific plasmid DNA integration into the
genome might be possible as well. Although the stimulated let-7a
expression by the ectopic HMGA2 overexpression was not entirely
proofed within this study the newly generated CT1258-EGFP-
HMGA2 cell line is nevertheless a suitable tool to further
investigate the impact of HMGA2 expression on other HMGA2
regulating and regulated genes in canine prostate cancer.
To further examine the role of ectopically overexpressed
HMGA2, the expression of the HMGA2-regulated targets
HMGA1, SNAI1, SNAI2 and the downstream target CDH1 was
analysed. These targets are of considerable interest as they were
described to be involved in the EMT and thus are able to promote
the invasion, migration and subsequent metastasis of prostate
cancer cells [72,73]. The analyses of the HMGA2-related family
member HMGA1 revealed a potential positive regulation by the
overexpression of the HMGA2-EGFP fusion protein. We could
show that HMGA1 was significantly higher expressed in CT1258-
EGFP-HMGA2 cells compared to native CT1258 and the
CT1258-EGFP control cell line. Interestingly, the HMGA1
transcript is also described to be negatively regulated by the same
let-7 mechanism as previously described for HMGA2 [35,74]. In
accordance with our results, Berlingieri et al. described in a
previous study a positive, HMGA2-dependent regulation of
HMGA1 in rat thyroid cells [48].
The analysis of the other HMGA2 targets SNAI1, SNAI2 and its
negatively regulated downstream target CDH1 [49] showed no
differences in expression except SNAI1. SNAI1 was significantly
lower expressed in the CT1258-EGFP but not significantly
different in CT1258-EGFP-HMGA2 compared to native
CT1258 cells.
The cell proliferation analyses by BrdU incorporation assay
showed that the ectopic overexpression of recombinant HMGA2-
EGFP in the CT1258-HMGA2-EGFP cell line resulted in a
significantly increased cell proliferation in comparison to native
CT1258 and CT1258-EGFP cells. The results revealed that native
CT1258 and CT1258-EGFP cells presented nearly the same
proliferative rate and thereby excluding that a cell proliferative
effect might be mediated by EGFP expression. Consequently the
seen effect can be attributed to the ectopic overexpression of
HMGA2 within the CT1258-HMGA2-EGFP cell line.
The present results are in accordance with other studies where
ectopic overexpression of recombinant HMGA2 was also shown to
have a positive effect on cell proliferation in e.g. rat fibroblasts
[75], or murine myeloblasts [76] in vitro and on hematopoietic
tissue derived from transgenic HMGA2-overexpressing mice [59].
The comparability of these pervious results and the proliferative
characteristics of CT1258-HMGA2-EGFP underline the func-
tionality of the introduced recombinant protein.
The cytogenetic analyses of the recombinant fluorescent cell
lines CT1258-EGFP and CT1258-HMGA2-EGFP revealed stable
chromosome copy numbers resembling the hyperdiploid karyo-
type with der(1;5) chromosomal fusions and the characteristic
large bi-armed marker chromosome mainly consisting of material
from CFA1 and CFA2 found in native CT1258 cells. The
karyotype of CT1258 native cells and their fluorescent derivatives
has changed slightly compared to cells of CT1258, which were
analysed in a very early passage by Winkler et al. in 2005 [45]. In
addition to the marker chromosome and the der(1;5) chromosome,
the centric fusion of CFA4 and CFA5 (der(4;5)) found in 50% of
the analysed metaphases of primary CT1258 cells [45] was no
longer present in the native CT1258 cells used in the present
study. This loss of der(4;5) can probably be explained due to
selection in direction to der(1;5) during the cultivation of the cells
over time as the der(4;5) was only found in 50% of the primary
analysed CT1258 cells. With the comparative cytogenetic we
could assure that no macroscopic chromosomal aberrations such
as fusions or breakpoints were induced by the transfection and
subsequent integration of the expression vectors pEGFP-C1 and
pEGFP-C1-HMGA2 into the genome under G418 antibiotic
selection pressure.
Cell lines represent a key tool in cancer research allowing
investigating complex interrelations of certain target genes in
tumour development in vitro in basic research experiments. With
the newly established canine CT1258-EGFP-HMGA2 cell line we
could demonstrate in vitro an increased cell-proliferative effect of
ectopic overexpressed EGFP-HMGA2. Moreover, the generated
data adds functional data helping to understand the complex
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regulation mechanisms between HMGA2, let-7a and further
selected targets in the progression of prostate cancer.
This CT1258-EGFP-HMGA2 cell line provides a valuable tool
to further decipher the HMGA2-mediated molecular mechanisms
of prostate cancer and to identify potential targets for development
of novel therapies.
Additionally, the ability of the CT1258-EGFP-HMGA2 cell line
to express an enhanced EGFP tagged HMGA2 fusion protein can
be utilised to monitor the in vivo behaviour of the cell line using
fluorescence imaging subcutaneously.
To further extend the presented in vitro findings, in vivo studies
need to be carried out. In perspective, this could allow to
characterise if abundantly expressed recombinant HMGA2 can
increase the highly tumourigenic potential of CT1258 which was
previously demonstrated in a murine NOD/SCID in vivo model
[46,47]. The first characterisation of this hypothesis needs to be
carried out carefully in an intermediary in vivo mouse model. Such
an HMGA2-overexpressing in vivo mouse model will help to
elucidate, if the previously described correlation between HMGA2
and the malignant and metastatic potential of prostate cancer [17]
can be reflected and to characterise the underlying molecular
mechanisms. Based on this, novel therapeutic options can be
established within an in vivo mouse model and subsequently
applied to treat dogs being affected by prostate cancer.
Xenograft mouse models with implanted human prostate
cancer cell lines such as LNCaP [77], PC-3 [78] or DU145 [79]
are extremely useful to study the biology of prostate cancer and are
used routinely in human research to evaluate prostate cancer
therapies. However, xenografts mouse models miss some impor-
tant characteristics of naturally occurring tumours which exper-
imentally induced tumours or tumours transplanted into immu-
nocompromised animals cannot provide and bear limitations
concerning metabolism, body size and age [80,81]. Thus, long
term disease studies are difficult to accomplish within mouse
models due to a short life span in comparison to humans [82].
Since prostate cancer develops in dogs spontaneously under the
surveillance of an intact immune system in a syngeneic host and
tumour microenvironment [83], the dog as a companion animal
model provides an important translational bridge between the
mouse xenografts and human clinical trials [10,84]. In fact, dogs
were suggested by the National Cancer Institute as a potential
population to incorporate into studies of new therapeutics [84,85].
Consequently, the dog’s contribution to translational research
provides reciprocal benefit for both species with the potential to
significantly enhance the understanding of prostate cancer
development and progression.
Conclusions
In conclusion, with the herein generated new fluorescent canine
CT1258-EGFP-HMGA2 cell line a stable highly reproducible tool
for further investigation of HMGA2-mediated cell proliferative
effects in vitro and in vivo in prostate cancer is provided. Screenings
as done herein exemplarily for the HMGA2 regulator let-7a and the
HMGA2 targets HMGA1, SNAI1, SNAI2 and CDH1 will help to
reveal the tumour acting mechanisms. The gained insights of
HMGA2-involvement in canine prostate cancer contribute to the
identification and evaluation of novel therapeutic options. As the
dog displays a unique animal model for prostate cancer, the
development of therapeutic strategies provides an important
contribution to translational research directed to treat humans,
thus providing benefit for both species.
Supporting Information
Figure S1 SNAI1 real-time PCR analyses. Relative SNAI1/
HPRT1 and SNAI1/GUSB expression in native CT1258, CT1258-
EGFP and CT1258-HMGA2-EGFP cells. Error bars are standard
deviations. *p#0.05 indicates a statistical significant deregulation
of SNAI1 expression in CT1258-EGFP when compared to native
CT1258 cells. The CT1258-EGFP-HMGA2 cell line showed no
statistical significant different SNAI1 expression in comparison to
native CT1258 cells.
(TIF)
Figure S2 SNAI2 real-time PCR analyses. Relative SNAI2/
HPRT1 and SNAI2/GUSB expression in native CT1258, CT1258-
EGFP and CT1258-HMGA2-EGFP cells. Error bars are standard
deviations. No statistical significant deregulation of SNAI2
expression was detected in CT1258-EGFP and CT1258-
HMGA2-EGFP when compared to native CT1258 cells. Statis-
tical significant p value was defined as #0.05.
(TIF)
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